The development of a non-invasive drug delivery system for unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) has been the elusive goal of several research groups since the initial discovery of this glycosaminogylcan by McLean in 1916. After a brief update on current parenteral formulations of UFH and LMWHs, this review revisits past and current strategies intended to identify alternative routes of administration (e.g. oral, sublingual, rectal, nasal, pulmonary and transdermal). The following strategies have been used to improve the bioavailability of this bioactive macromolecule by various routes: (i) enhancement in cell-membrane permeabilization, (ii) modification of the tight-junctions, (iii) increase in lipophilicity and (iv) protection against acidic pH of the stomach. Regardless of the route of administration, a simplified unifying principle for successful non-invasive macromolecular drug delivery may be: "to reversibly overcome the biological, biophysical and biochemical barriers and to safely and efficiently improve the in vivo spatial and temporal control of the drug in order to achieve a clinically acceptable therapeutic advantage". Future macromolecular drug delivery research should embrace a more systemic approach taking into account recent advances in genomics/proteomics and nanotechnology.

ABSTRACT:The purpose of this study was to prepare, characterize, and evaluate genistein-containing microparticles with enhanced dissolution profile using poly(ethylene glycol) (PEG) as polymer matrix. Genistein loaded microparticles were prepared by a solvent evaporation process and their surface, thermal, chemical, and dissolution properties were analyzed by microscopy, differential scanning calorimetry, ATR-FTIR spectroscopy, and USP dissolution apparatus II, respectively. The wettability index was also determined. Genistein exhibited an elongated crystal habit. However, the drug containing PEG microparticles were discrete and quasispherical. The ATR-FTIR studies performed on the formulation suggested hydrogen bonding between the drug and the polymer matrix. Thermal analysis indicated a conversion of the crystalline form of the drug to an amorphous form. Genistein, exhibiting low solubility and high permeability, is a Class II drug of the Biopharmaceutical Classification Scheme. However, there was a ϳ9-fold increase in the rate of dissolution of genistein in the case of all formulations as compared to native genistein. This study showed that genistein could be effectively encapsulated into PEG microparticles using an emulsion-solvent evaporation technique, therefore avoiding the potential disadvantages of other solid dispersion techniques. This approach provided a significant enhancement in the drug dissolution profile.

The primary objective of this study was to evaluate sodium caprate as an oral penetration enhancer for low molecular weight heparin (LMWH), ardeparin. In vitro studies using Caco-2 cell monolayer indicated that 0.0625% of sodium caprate gave approximately 2-fold enhancement of ardeparin compared to negative control with almost 100% cell survival as evaluated by MTT cytotoxicity assay. In vivo studies in rats with ardeparin (1200 IU/kg) and sodium caprate (100 mg/kg) led to a relative bioavailability of 27% with plasma anti-factor Xa levels within the therapeutic range (> 0.2 IU/ml). Moreover, under these conditions, histological examination provided evidence that there was no damage to the gastrointestinal wall. Regional permeability studies using rat intestine indicated the colon as the region of maximum permeation. These results suggest that, at the dose administered, sodium caprate acts as a relatively safe and efficient absorption enhancer in the quest for alternatives for the oral delivery of LMWH.